ESP Bioscience is set to launch Diabetic Hypoglycaemia (http://www.hypodiab.com) an influential new online diabetes journal delivering information on basic science; human physiology and clinical and educational communications about hypoglycaemia. Created with, and run by an editorial board of hypoglycaemia experts led by Professor Brian Frier (Edinburgh, UK) with Associate editors: Simon Heller (Sheffield, UK); Christopher Ryan (Pittsburgh, USA) and Rory McCrimmon (Yale, USA), Diabetic Hypoglycaemia will be published three times per year and will provide an interactive forum for readers to share practical knowledge and opinions on the rapidly evolving issue that is hypoglycaemia. “Diabetic Hypoglycaemia will provide an essential new source of hypoglycaemia awareness for those people in diabetes care and research who have an interest in this important field” commented the editors of Diabetic Hypoglycaemia “Our goal is to create an open access and independent online journal advancing hypoglycaemia care and research through information sharing, topical review and expert discussion”. Initial support of the journal is provided by an unrestricted educational grant from Novo Nordisk A/S (Bagsvaerd, Denmark).

Please visit the journal website at http://www.hypodiab.com/ for a free view of content.

About ESP Bioscience

ESP Bioscience (a division of ESP Limited) is a publisher of novel and new medical information products and online medical communities with headquarters in Sandhurst, United Kingdom. Working in association with its academic partners in the global healthcare community, ESP Bioscience publishes journals, books and online resources.

Contact:

Roger Pettis, ESP Bioscience
E: roger@espstc.com
T: +44 (0) 1344762531
F: +44 (0) 203 0514753